Bausch Health Wins DUOBRII(R) and BRYHALI(R) Patent Infringement Case
Bausch Health Companies (NYSE/TSX:BHC) announced a favorable ruling from the US District Court for the District of New Jersey regarding its products DUOBRII and BRYHALI. The court upheld the validity of all asserted patents, preventing the approval of generics by Padagis Israel Pharmaceuticals until the patents expire in 2031 and 2036, respectively. This decision reinforces Bausch Health's commitment to its patent portfolio and the strength of its intellectual property. DUOBRII and BRYHALI are both topical medications for treating plaque psoriasis.
- Court ruling upheld the validity of BHC's patents for DUOBRII and BRYHALI.
- Decision prevents generic competition from Padagis until patent expiry dates in 2031 and 2036.
- Strengthens Bausch Health's intellectual property and market position.
- None.
LAVAL, QB / ACCESSWIRE / December 2, 2022 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced that the US District Court for the District of New Jersey issued a favorable decision regarding DUOBRII® and BRYHALI®, in a suit filed against Padagis Israel Pharmaceuticals LTD and Padagis US LLC. According to the ruling, the District Court found all the asserted patents valid and infringed. The current decision will serve to prevent approval of Padagis BRYHALI® and DUOBRII® generics until patent expiry in 2031 and 2036, respectively.
DUOBRII® (halobetasol propionate and tazarotene) Lotion,
Seana Carson, Executive Vice President and General Counsel stated, "We are pleased with this outcome. This decision is a reflection of the strength of our intellectual property, and our commitment to defending our patent portfolio."
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
This news release may contain forward-looking statements about the future performance of Bausch Health which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
###
Investor Contact:
Christina Cheng
ir@bauschhealth.com
(514) 856-3855
(877) 281-6642 (toll free)
Media Contacts:
Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785
SOURCE: Bausch Health Companies Inc
View source version on accesswire.com:
https://www.accesswire.com/729811/Bausch-Health-Wins-DUOBRIIR-and-BRYHALIR-Patent-Infringement-Case
FAQ
What was the recent court ruling for Bausch Health (BHC)?
How does the court ruling affect Bausch Health's products DUOBRII and BRYHALI?
When do the patents for DUOBRII and BRYHALI expire?
What is the significance of the court ruling for Bausch Health investors?
